Citations

Clear

9383 citation(s) found for "Thomas, PS".

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi, Ayalew , Cervantes, Francisco , Passamonti, Francesco , Verstovšek, Srđan , Dupriez, Brigitte, Pardanani, Animesh , Harrison, Claire , Gisslinger, Heinz , Thiele, Jüergen, Barbui, Tiziano , Mesa, Ruben A. , Vannucchi, Alessandro M. , Gotlib, Jason , Hoffman, Ronald , Kröger, Nicolaus , Barosi, Giovanni , Verstovsek, Srdan , Passamonti, Francesco

Mayo Clinic

Blood | July 9, 2013 | Volume: 122 | Issue: 8 | Pages: 1395-1398

10.1182/blood-2013-03-488098 | PMID 23838352 Get It

Key Points Treatment response criteria for MF must capture drug benefit in terms of symptom burden. The current document includes stricter definitions of red cell transfusion need and independence.
Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation
Czuczman, Myron S., Zinzani, Pier Luigi , Reeder, Craig B. , Tuscano, Joseph M. , Lossos, Izidore S. , Pietronigro, Dennis, Vose, Julie M. , Habermann, Thomas M. , Li, Ju , Witzig, Thomas E. , Zinzani, Pier Luigi

Mayo Clinic

British Journal of Haematology | July 9, 2013 | Volume: 162 | Issue: 5 | Pages: 639-647

10.1111/bjh.12449 | PMID 23834234 Get It

SummaryPatients with aggressive non‐Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL‐002 and NHL‐003) that studied single‐agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B‐cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression‐free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5‐month follow‐up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single‐agent lenalidomide.
Participation in Cardiac Rehabilitation and Survival After Coronary Artery Bypass Graft Surgery
Pack, Quinn R. , Lahr, Brian D. , Greason, Kevin L. , Squires, Ray W. , Thomas, Randal J. , Goel, Kashish , López-Jiménez, Francisco , Zhang, Zixin , Thomas, Randal

Mayo Clinic

Circulation | July 9, 2013 | Volume: 128 | Issue: 6 | Pages: 590-597

10.1161/circulationaha.112.001365 | PMID 23836837 Get It

Background— Cardiac rehabilitation (CR) is recommended for all patients after coronary artery bypass surgery, yet little is known about the long-term mortality effects of CR in this population. Methods and Results— We performed a community-based analysis on residents of Olmsted County, Minnesota, who underwent coronary artery bypass surgery between 1996 and 2007. We assessed the association between subsequent outpatient CR attendance and long-term survival. Propensity analysis was performed. Cox proportional hazards regression was then used to assess the association between CR attendance and all-cause mortality adjusted for the propensity to attend CR. We identified 846 eligible patients (age 66±11 years, 76% men, and 96% non-Hispanic whites) who survived at least 6 months after surgery, of whom 582 (69%) attended CR. During a mean (±SD) follow-up of 9.0±3.7 years, the 10-year all-cause Kaplan-Meier mortality rate was 28% (193 deaths). Adjusted for the propensity to attend CR, participation in CR was associated with a 10-year relative risk reduction in all-cause mortality of 46% (hazard ratio, 0.54; 95% confidence interval, 0.40–0.74; P <0.001) and a 10-year absolute risk reduction of 12.7% (number needed to treat=8). There was no evidence of a differential effect of CR on mortality with respect to age (≥65 versus <65 years), sex, diabetes, or prior myocardial infarction. Conclusions— CR attendance is associated with a significant reduction in 10-year all-cause mortality after coronary artery bypass surgery. Our results strongly support national standards that recommend CR for this patient group.
Human Calmodulin-Like Protein CALML3: A Novel Marker for Normal Oral Squamous Mucosa That Is Downregulated in Malignant Transformation
Brooks, Michael , Bennett, Richard D., Weaver, Amy L. , Sebo, Thomas J., Eckert, Steven E, Strehler, Emanuel E. , Carr, Alan B.

Mayo Clinic

International Journal of Dentistry | July 8, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-8

10.1155/2013/592843 | PMID 23935623 Get It

Oral cancer is often diagnosed only at advanced stages due to a lack of reliable disease markers. The purpose of this study was to determine if the epithelial-specific human calmodulin-like protein (CALML3) could be used as marker for the various phases of oral tumor progression. Immunohistochemical analysis using an affinity-purified CALML3 antibody was performed on biopsy-confirmed oral tissue samples representing these phases. A total of 90 tissue specimens were derived from 52 patients. Each specimen was analyzed in the superficial and basal mucosal cell layers for overall staining and staining of cellular subcompartments. CALML3 was strongly expressed in benign oral mucosal cells with downregulation of expression as squamous cells progress to invasive carcinoma. Based on the Cochran-Armitage test for trend, expression in the nucleus and at the cytoplasmic membrane significantly decreased with increasing disease severity. Chi-square test showed that benign tissue specimens had significantly more expression compared to dysplasia/CIS and invasive specimens. Dysplasia/CIS tissue had significantly more expression than invasive tissue. We conclude that CALML3 is expressed in benign oral mucosal cells with a statistically significant trend in downregulation as tumorigenesis occurs. CALML3 may thus be a sensitive new marker for oral cancer screening.
Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement
Wang, Zhiwei , Zhang, Mei‐Jie , Bolwell, Brian J., Chen, Andy I. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Hayes‐Lattin, Brandon , Holmberg, Leona , Inwards, David J. , Isola, Luis , Khoury, H. Jean , Lewis, Victor , Maharaj, Dipnarine , Munker, Reinhold , Phillips, Gordon L., Rizzieri, David A. , Rowlings, Philip A., Saber, Wael , Satwani, Prakash , Waller, Edmund K. , Maloney, David G. , Montoto, Silvia , Laport, Ginna G. , Hari, Parameswaran , Holmberg, Leona , Chen, Andy , Maziarz, Richard Thomas , Gale, Robert Peter , Vose, Julie M. , Lazarus, Hillard M. , Waller, Edmund K , Montoto, Silvia , Hari, Parameswaran

Mayo Clinic

British Journal of Haematology | July 6, 2013 | Volume: 162 | Issue: 5 | Pages: 648-656

10.1111/bjh.12451 | PMID 23829536 Get It

SummaryPre‐existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non‐Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS+) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS−). There were significant baseline differences between the cohorts. CNS+ patients were more likely to be younger, have lower performance scores, higher age‐adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression‐free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS+ group with a subset of CNS− patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS+ patients can achieve excellent long‐term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.
CYP2B6*6 is associated with increased breast cancer risk
Justenhoven, Christina , Pentimalli, Daniela, Rabstein, Sylvia , Lotz, Anne , Pesch, Beate, Brüning, Thomas , Dörk, Thilo , Schürmann, Peter , Bogdanova, Natalia , Park‐Simon, Tjoung‐Won, Couch, Fergus J. , Fasching, Peter A. , Beckmann, Matthias W. , Häberle, Lothar , Ekici, Arif B. , Czene, Kamila , Liu, Janjun, Li, Jingmei , Baisch, Christian, Hamann, Ute , Ko, Yon‐Dschun, Brauch, Hiltrud , Harth, Volker , Park‐Simon, Tjoung‐Won , Couch, Fergus J. , Olson, Janet E. , Hall, Per N , Dörk, Thilo , Li, Jingmei , Ekici, Arif B , Bogdanova, Natalia V , Czene, Kamila , Brauch, Hiltrud

Mayo Clinic

International Journal of Cancer | July 3, 2013 | Volume: 134 | Issue: 2 | Pages: 426-430

10.1002/ijc.28356 | PMID 23824676 Get It

The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry assay. The GENICA breast cancer case–control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.
Research Priority Setting
Vickrey, Barbara G. , Brott, Thomas G. , Koroshetz, Walter J.

Mayo Clinic

Stroke | July 3, 2013 | Volume: 44 | Issue: 8 | Pages: 2338-2342

10.1161/strokeaha.113.001196 | PMID 23821224 Get It

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
Ivan, Cristina , Shimizu, Masayoshi , Rabe, Kari G. , Nouraee, Nazila , Ikuo, Mariko, Ghosh, Asish K. , Rassenti, Laura Z., Xiao, Lianchun , Hu, Jianhua , Reuben, James M. , Calin, Steliana , You, M. James , Manning, John T. , Wierda, William G. , Keating, Michael J. , Călin, George A. , Calin, George A. , Ferrajoli, Alessandra , Shanafelt, Tait D. , Lerner, Susan A. , Wierda, William G. , Estrov, Zeev E. , O’Brien, Susan , Kipps, Thomas J. , Kay, Neil E. , Chaffee, Kari G.

Mayo Clinic

Blood | July 3, 2013 | Volume: 122 | Issue: 11 | Pages: 1891-1899

10.1182/blood-2013-01-478222 | PMID 23821659 Get It

Key Points miR-155 levels are significantly and increasingly overexpressed as normal B cells progress to MBL and to CLL. Plasma levels of miR-155 before treatment were significantly lower in patients with CLL who experienced complete response than in all others.
Clinical Features and Treatment Responses in Pediatric Lymphocytic and Collagenous Colitis
Narla, Nirmala P. , Smyrk, Thomas C. , Pardi, Darrell S. , Tung, Jeanne

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 2, 2013 | Volume: 57 | Issue: 5 | Pages: 557-561

10.1097/mpg.0b013e3182a1df59 | PMID 23820404 Get It

ABSTRACTObjective:Microscopic colitis (MC) is prevalent in adults investigated for chronic watery diarrhea, yet characterization of pediatric MC is limited.Methods:Our pathology database was searched from 1995 to 2011 for pediatric cases of lymphocytic colitis (LC) or collagenous colitis (CC). Those with diarrhea persisting for >2 weeks and visually normal colonoscopy were accepted as cases. Demographics, laboratory results, medication use within 3 months of presentation, medical and family history of autoimmune disease, and response to treatment were abstracted.Results:A total of 27 cases were histologically consistent with MC on biopsy; 5 with concomitant enteric infection or isolated abdominal pain were excluded. Twenty‐two cases of MC (female patients, 59%; median age at diagnosis, 15.3 years) were included (19 LC and 3 CC). Two had type 1 diabetes mellitus, 2 were anti‐nuclear antibody positive, and 2 had common variable immunodeficiency. Of 20 patients who underwent an esophagogastroduodenoscopy, 1 had collagenous sprue and 4 had celiac disease. One presented after the clearance of recurrent Clostridium difficile infection. Previous drug exposures included nonsteroidal anti‐inflammatory drugs (n = 7), proton pump inhibitors (n = 6), and selective serotonin reuptake inhibitors (n = 3). Common symptoms in addition to diarrhea included abdominal pain (77.3%) and weight loss (27.3%). Of 17 patients with follow‐up, all of the 8 treated with steroids had some response: 57.1% (4/7) responded to mesalamine and 42.9% (3/7) responded to bismuth subsalicylate.Conclusions:In this cohort of pediatric patients, LC was much more common than CC. As described in adults, we observed associations with celiac disease, type 1 diabetes mellitus, and medications; we additionally saw an association with immunodeficiency. Our patients showed greater response to steroids than mesalamine or bismuth.
Risk-stratified imputation in survival analysis
Kennedy, Richard , Adragni, Kofi P. , Tiwari, Hemant K., Voeks, Jenifer H. , Brott, Thomas G. , Howard, George , Kennedy, Richard E , Howard, George

Mayo Clinic

Clinical Trials | July 2, 2013 | Volume: 10 | Issue: 4 | Pages: 530-539

10.1177/1740774513493150 | PMID 23818434 Get It

Background Censoring that is dependent on covariates associated with survival can arise in randomized trials due to changes in recruitment and eligibility criteria to minimize withdrawals, potentially leading to biased treatment effect estimates. Imputation approaches have been proposed to address censoring in survival analysis; while these approaches may provide unbiased estimates of treatment effects, imputation of a large number of outcomes may over- or underestimate the associated variance based on the imputation pool selected. Purpose We propose an improved method, risk-stratified imputation, as an alternative to address withdrawal related to the risk of events in the context of time-to-event analyses. Methods Our algorithm performs imputation from a pool of replacement subjects with similar values of both treatment and covariate(s) of interest, that is, from a risk-stratified sample. This stratification prior to imputation addresses the requirement of time-to-event analysis that censored observations are representative of all other observations in the risk group with similar exposure variables. We compared our risk-stratified imputation to case deletion and bootstrap imputation in a simulated dataset in which the covariate of interest (study withdrawal) was related to treatment. A motivating example from a recent clinical trial is also presented to demonstrate the utility of our method. Results In our simulations, risk-stratified imputation gives estimates of treatment effect comparable to bootstrap and auxiliary variable imputation while avoiding inaccuracies of the latter two in estimating the associated variance. Similar results were obtained in analysis of clinical trial data. Limitations Risk-stratified imputation has little advantage over other imputation methods when covariates of interest are not related to treatment. Risk-stratified imputation is intended for categorical covariates and may be sensitive to the width of the matching window if continuous covariates are used. Conclusions The use of the risk-stratified imputation should facilitate the analysis of many clinical trials, in which one group has a higher withdrawal rate that is related to treatment.